• A M Hong, D Jones, R Boyle, and P Stalley.
• Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Department of Radiation Oncology, Chris O'Brien Lifehouse, Camperdown, Australia. Electronic address: angela.hong@sydney.edu.au.
• Clin Oncol (R Coll Radiol). 2018 Sep 1; 30 (9): 589-592.

AimTo determine the outcome after radiation therapy for desmoid fibromatosis.Materials And MethodsA retrospective review of 50 patients treated between 1988 and 2016 in a specialised bone and soft tissue tumour clinic.ResultsThe median age at the time of radiation therapy was 36.8 years (range 15.1-69.0) and the median follow-up time was 51 months. Forty-three patients underwent radiation therapy as the definitive treatment with a median dose of 56 Gy (range 30-58.8 Gy). The median dose for the seven patients treated with postoperative radiation therapy was 50.4 Gy (range 48-56 Gy). Eleven patients (22%) developed progressive disease after radiation therapy at a median time of 41 months (range 12-113 months). The recurrences were within the radiation therapy field in four patients and outside the field in seven patients. One patient developed a radiation-induced malignancy 20 years after treatment.ConclusionsRadiation therapy is an alternative treatment in the management of desmoid fibromatosis. It should be considered in patients for whom surgical resection is not feasible, or as adjuvant therapy after surgery with involved margins where any further recurrences would cause significant morbidity.Crown Copyright © 2018. Published by Elsevier Ltd. All rights reserved.

31 keywords...

hide…